Patients having a HR+ tumor with mutations of PIK3CA (P=0.006), a combination of mutations and gain of PIK3CA (P=0.001), a combined aberration of PIK3CA, PTEN and INPP4B (P=0.002), and gain of FOXA1 (P=0.002), CDH3 (P=0.007), BIRC5 (P=0.016), MYBL2 (P=0.015), and AIB1 (P=0.006) had worse RFS rates than patients having a HR+ tumor without (Table 4). Here, MYBL2 is linked to neoplasm.